Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | S100B | P04271 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9469338 | 0.98 | NOS2 (0.46) | NOS2SKP2POLBKDM4ETSHR | |
| SCHEMBL9359662 | 0.88 | SKP2 (0.53) | NOS2SKP2POLBKDM4ETSHR | |
| SCHEMBL28264934 | 0.84 | NOS2 (0.52) | NOS2SKP2POLBKDM4ETSHR | |
| SCHEMBL5329916 | 0.84 | SKP2 (0.46) | SKP2KDM4EALDH1A1CYP3A4ESR1 | |
| SCHEMBL11345756 | 0.84 | SKP2 (0.46) | SKP2KDM4EALDH1A1CYP3A4ESR1 | |
| SCHEMBL2495189 | 0.83 | NOS2 (0.52) | NOS2SKP2POLBKDM4ETSHR | |
| SCHEMBL2954428 | 0.80 | NOS2 (0.42) | NOS2SKP2POLBKDM4ETSHR | |
| SCHEMBL458150 | 0.79 | NOS2 (0.45) | NOS2SKP2POLBKDM4ETSHR | |
| SCHEMBL8812744 | 0.79 | ALDH1A1 (0.34) | NOS2SKP2POLBKDM4ETSHR | |
| SCHEMBL10383853 | 0.79 | NOS2 (0.40) | NOS2SKP2POLBKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | NOS2 185/4885SKP2 3308/4885POLB 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.